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Abstract
 
Puumala virus (PUUV) is a hantavirus that causes hemorrhagic fever with renal syndrome
(HFRS), which is an important public health problem in large parts of Europe. We examined
the memory cytolytic T lymphocyte (CTL) responses in 13 Finnish individuals who had
HFRS between 1984 and 1995. In seven of these donors, we detected virus-specific CTL re-
sponses against the PUUV nucleocapsid (N) protein after in vitro stimulation with PUUV. Six
novel CD8
 
 
 
 CTL epitopes were defined on the N protein and were found to be restricted by
various HLA alleles including A2, A28, B7, and B8. This is the first demonstration of PUUV-
specific CTL responses in humans, and the first identification of CTL epitopes on PUUV. In
addition, this study provides one of the few characterizations of a human antiviral memory T
cell response, without the complicating issues of virus persistence or reinfection. Interferon
(IFN)-
 
 
 
 ELISPOT analysis showed that memory CTL specific for these epitopes were present
at high frequency in PUUV-immune individuals many years after acute infection in the ab-
sence of detectable viral RNA. The frequencies of PUUV-specific CTL were comparable to or
exceeded those found in other viral systems including influenza, EBV and HIV, in which CTL
responses may be boosted by periodic reinfection or virus persistence.
Key words: Puumala virus • hantavirus • immunologic memory • cytotoxic T lymphocytes • 
T lymphocyte epitopes
 
Introduction
 
Puumala virus (PUUV)
 
*
 
, a member of the Hantavirus ge-
nus, causes a mild form of hemorrhagic fever with renal
syndrome (HFRS), also known as nephropathia epidemica.
PUUV is endemic primarily in Northern and central Eu-
rope and western parts of Russia and is responsible for
 
 
 
4,000–6,000 clinical cases of HFRS annually with a mor-
tality rate of 
 
 
 
1%. PUUV infections usually result in a mild
form of HFRS, but can also result in a more serious form
of the disease characterized by renal failure and circulatory
shock. Other hantaviruses that cause more severe forms of
HFRS include Hantaan virus (HTNV; Asia) and Dobrava
virus (DOBV; Balkans). Related hantaviruses in North and
South America (e.g., Sin Nombre [SNV] and Andes
[ANDV] virus) cause a frequently fatal pulmonary infection
known as hantavirus pulmonary syndrome (HPS). HFRS
and HPS are distinct in the primary target organ of virus
infection (kidney versus lung) but have important clinical
features in common including fever, thrombocytopenia,
and a capillary leak syndrome. These common clinical
manifestations suggest that the underlying mechanisms of
disease may be similar in the two syndromes.
The pathogenesis of hantavirus infection is not well un-
derstood. Endothelial cells and monocytes are thought to
be the primary cell types infected by the virus, but infec-
tion has no direct cytopathic effect on these cells (1–5).
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Therefore, it is unlikely that direct viral cytotoxicity is the
primary cause of pathology in vivo. Several studies have
suggested that the clinical syndromes caused by hantavirus
infection may be mediated in part by immunopathologic
mechanisms, including the action of virus-specific CD8
 
 
 
and CD4
 
 
 
 T lymphocytes. Evidence to suggest this in-
cludes increases in the numbers of activated circulating
CD8
 
 
 
 T cells that are seen during HFRS (6), and infiltrat-
ing lymphocytes (predominantly CD8
 
 
 
 T cells) found in
kidney biopsies from patients with acute PUUV infections
(7, 8). In addition, elevated levels of T cell–derived cyto-
kines such as TNF-
 
 
 
 and IFN-
 
 
 
 have been observed in both
the kidney and peripheral blood of patients with acute han-
tavirus infections (8–11), and increased numbers of cyto-
kine-producing cells were seen in the lungs of patients with
fatal HPS compared with patients with non-HPS acute re-
spiratory distress syndrome (12). Further, a recent study by
Mustonen et al. (13) demonstrated a correlation between
severity of disease caused by PUUV infection and the HLA
haplotype B8, DR3, suggesting that T cells restricted by
these HLA alleles may impact the severity of disease.
To begin to understand the role of T lymphocytes in
human hantavirus infection, we analyzed memory T cell
responses in a group of 13 Finnish individuals who had
clinical PUUV infections between the years 1984 and
1995. We were able to demonstrate PUUV-specific T cell
responses in seven individuals with the N protein being
the most commonly recognized viral protein. We identi-
fied six novel CD8
 
 
 
 CTL epitopes on the N protein and
found that frequencies of memory CD8
 
 
 
 T cells specific
for a single viral epitope were as high as 100–300 per 10
 
6
 
PBMCs for up to 15 y after the acute infection. The in-
ability to detect viral RNA in either PBMCs or urine from
these and other PUUV immune individuals suggested that
virus-specific memory T cells were maintained in the ab-
sence of persistent virus. As such, the PUUV system pro-
vides an ideal opportunity to study the development and
maintenance of antiviral T cell memory in humans. In ad-
dition, the identification of CD8
 
 
 
 T cell epitopes on
PUUV will allow us to track specific antiviral T cell re-
sponses during acute HFRS, which will provide insight
into the role of T cells in the recovery from and/or the
immunopathology of disease.
 
Materials and Methods
 
Study Subjects.
 
Donors were Finnish individuals who had
HFRS caused by PUUV infection between the years 1984 and
1995. The diagnosis of PUUV infection was confirmed by sero-
logical detection of PUUV-specific antibodies (13). PBMCs were
isolated from 60 mls of whole blood using CPT vacutainer tubes
(Becton Dickinson). Cells were resuspended at 1–2
 
   
 
10
 
7
 
/ml in
RPMI 1640 supplemented with 20% FBS (Sigma-Aldrich), 2 ml
 
L
 
-glutamine, 50 U/ml penicillin, 50 
 
 
 
g/ml streptomycin, and
10% DMSO and cryopreserved until use.
 
Synthetic Peptides.
 
Overlapping peptides that spanned the
PUUV strain K27 nucleocapsid protein were synthesized based
on the published sequence (14) (GenBank/EMBL/DDBJ acces-
sion no. L08804). Peptides were 15 amino acids in length and
 
overlapped by nine amino acids. Peptides were synthesized at the
Protein Chemistry Core Facility at the University of Massachu-
setts Medical School using an automated Rainin Symphony pep-
tide synthesizer.
 
In Vitro Stimulation of PBMCs.
 
5–7
 
   
 
10
 
6
 
 PBMCs were re-
suspended in 1 ml of AIM-V medium (Life Technologies) sup-
plemented with 10% human AB serum (Advanced Biotechnolo-
gies). The PBMCs were stimulated with 20 
 
 
 
l of purified PUUV
(2.6 
 
 
 
 10
 
6
 
 pfu/ml) (strain K27, provided by Connie S. Schmal-
john, US Amriid, Frederick, MD), grown in Vero E6 cells and
purified as described previously (15). Recombinant human IL-2
(5 U/ml) was added on days 5 and 6 of culture in fresh AIM-
V/10% human AB serum and the medium was replenished every
third day thereafter. 
 
51
 
[Cr]release cytotoxicity assays were per-
formed on days 7 and 8 of culture as described previously (16).
Target cells were autologous EBV-transformed B lymphoblastoid
cell lines (BLCLs) infected with vaccinia virus recombinants ex-
pressing PUUV N, glycoprotein 1 (G1), or glycoprotein 2 (G2).
Vaccinia virus recombinants were constructed as described previ-
ously (17). Unlabeled BLCLs infected with wild-type vaccinia vi-
rus were included in 
 
51
 
[Cr]release assays to reduce levels of
vaccinia-specific background lysis (10:1 unlabeled targets:
 
51
 
[Cr]
labeled targets). Cultures were maintained and all experiments
performed in a biosafety level 3 laboratory according to standard
BSL3 guidelines.
 
CTL Lines.
 
PUUV-specific CTL lines were established from
bulk cultures by limiting dilution cloning, as described previously
(16). In brief, cells were plated at 1, 3, or 10 cells per well in 96-
well, round-bottomed plates (Costar) in 0.5 ml AIM-V/10% FBS
and stimulated every 14 d with anti-CD3 (12F6; 0.1 
 
 
 
g/ml), re-
combinant human IL-2 (20 U/ml) and 
 
 
 
-irradiated, allogeneic
feeder cells (10
 
5
 
 cells per well). Individual wells containing virus-
specific CTL were identified by analysis of lytic activity against
autologous BLCLs infected with recombinant vaccinia viruses
expressing PUUV N, G1, or G2. Wells containing virus-specific
CTL were expanded into 48-well plates and restimulated every
14 d as described above. Surface expression of CD4 and CD8 was
determined by flow cytometry using FITC-conjugated antibodies
(Becton Dickinson). All cell lines were 
 
 
 
95% pure CD8 or CD4
as indicated. HLA restriction of CTL lines was determined using
partially HLA-matched BLCL targets infected with a vaccinia vi-
rus recombinant expressing PUUV N. Fine specificity of CTL
lines was determined using overlapping synthetic peptides that
span the PUUV N protein and subsequent N- and COOH-ter-
minal peptide truncations.
 
IFN-
 
 
 
 ELISPOT Assays.
 
Cryopreserved PBMCs were thawed
and incubated for 20–24 h in RPMI 1640/10% FBS. ELISPOT
assays were then performed as described previously (18). In brief,
96-well filtration plates (MAIPS45; Millipore) were coated with
15 
 
 
 
g/ml mouse anti–human IFN-
 
 
 
 mAb (clone N1B42; BD
PharMingen) overnight. PBMCs were plated at 2–5 
 
  
 
10
 
5
 
 cells
per well in RPMI 1640/10% FBS. Peptides were added at 10
 
 
 
g/ml and plates incubated for 16–18 h at 37
 
 
 
C. Biotinylated
mouse anti–human IFN-
 
 
 
 mAb (clone 4S.B3; BD PharMingen)
was added for 2 h at room temperature followed by streptavidin
alkaline phosphatase (1:400 dilution) for 45 min at room
temperature. Substrate (3-amino-9-ethyl-carbazole/0.15%H
 
2
 
O
 
2
 
)
(Sigma-Aldrich) was added for 10 min at room temperature.
PBMCs stimulated with phytohemagglutinin (2.5 
 
 
 
g/ml) were
used as a positive control and unstimulated PBMCs as a nega-
tive control. The number of spots in negative control wells (range
of 0–5 spots) was subtracted from the number of spots in stimu-
lated wells. T cell frequency was calculated as the number of 
581
 
Van Epps et al.
 
visible spots/number of total PBMCs per well, and the frequency
presented as the number of IFN-
 
 
 
 producing cells/10
 
6
 
 PBMCs.
Peptide stimulations were performed in triplicate wells unless in-
dicated otherwise. All ELISPOT experiments were performed at
least twice and mean values are shown. Responses were consid-
ered significant if a minimum of five IFN-
 
 
 
–producing cells were
present in the well and if the number of IFN-
 
 
 
–producing cells
was at least twice that of the negative control (18).
 
Results
 
PUUV Nucleocapsid (N) Protein Is a Dominant Target of
Memory CTL after Resolution of HFRS.
 
T cell responses
against PUUV have not been characterized. To identify
PUUV proteins that are targeted by the T cell response
during infection, PBMCs from 11 donors who had HFRS
caused by PUUV between the years 1984 and 1995 were
stimulated in vitro for 7–8 d with live PUUV. After in
vitro stimulation, bulk cultures were screened for recogni-
tion of autologous BLCLs infected with recombinant vac-
cinia viruses expressing PUUV proteins. CTL responses
against one or more PUUV protein were detectable in
PBMC from 7/11 donors tested. Virus-specific CTL rec-
ognized N protein in 6 of the cultures (donors 1–6), the
G1 glycoprotein in 5 (donors 1, 3, 5, 6, and 7), and the
G2 glycoprotein in 2 (donors 3 and 6) of the cultures (Fig.
1). After restimulation with PUUV and autologous, irra-
diated PBMCs, we were able to detect N-specific CTL in
bulk cultures from two of the donors in which virus-spe-
cific responses were undetectable at days 7 and 8 (unpub-
lished data). High levels of background lysis were detected
in the bulk cultures from three donors (donors 4, 5, and
7), despite the inclusion of unlabeled vaccinia virus-
infected target cells. This background may be due to NK
cell activity, although this possibility was not formally
tested. The background lysis in these cultures was 26, 18,
and 29%, respectively. However, the lysis of target cells
infected with recombinant viruses expressing PUUV pro-
teins was significantly higher than control target cells in-
fected with wild-type vaccinia virus. Lysis of vaccinia vi-
rus-infected targets in all other cultures was 
 
 
 
5%. The
specific lysis of targets infected with vaccinia virus recom-
binants expressing PUUV proteins was considered to be
positive if it was 
 
 
 
10% above lysis of WT vaccinia virus-
infected targets.
PUUV-specific CTL cell lines were identified and char-
acterized by in vitro expansion and cloning of bulk cultures
from donors 1 and 2. 43 PUUV-specific cell lines were iso-
lated from donor 1, of these 42 were N-specific and 1 was
G1-specific. 20 cell lines were isolated from donor 2, of
these 19 were N-specific and 1 was G2-specific. The pre-
dominance of cell lines specific for N suggests that epitopes
on the N protein may be the major target of the CTL re-
sponse during PUUV infection.
 
PUUV Infection Induces a Broad CTL Response to N Protein
in Two Individuals.
 
N-specific CTL lines isolated from
donors 1 and 2 were characterized using a panel of overlap-
ping 15-mer peptides that span the PUUV N sequence.
 
Optimal CTL epitopes were then defined by testing each
CTL line against sequential N- and COOH-terminal trun-
cations of the appropriate15-mer peptide (unpublished
data). The restricting HLA alleles required for peptide rec-
ognition by these CTL lines was determined using a panel
of partially HLA-matched BLCLs as targets in 
 
51
 
[Cr]release
assays. A summary of the epitopes and representative CTL
lines identified from these donors is shown in Table I.
CD8
 
 
 
 CTL lines from donor 1 were found to recognize
one of four epitopes: 1 restricted by HLA-A2 (N
 
204–12
 
), 1
restricted by B7 (N
 
173–81
 
), and two restricted by B8 (N
 
173–81
 
,
N
 
243–51
 
). CD8
 
 
 
 CTL lines from donor 2 also recognized
one of four epitopes: 1 restricted by HLA-A2 (N
 
204–12;
 
 not
shown), 1 restricted by A28 (N
 
164–78
 
) and 2 (N
 
236–50
 
, N
 
212–20
 
)
for which the restricting HLA allele has yet to be deter-
mined (Table I). Fig. 2 demonstrates the cytolytic activity
of the CD8
 
 
 
 CTL lines using target cells pulsed with in-
creasing peptide dilutions.
The CTL lines specific for N
 
204–212
 
 appeared to have a
range of affinities for the peptide/MHC complex, as re-
flected by the wide range of peptide concentrations re-
quired for sensitization of target cells (Fig. 2 A). This sug-
gests that the CTL response to this epitope is polyclonal.
This peptide (GLFPTQIQV) conforms to the defined
HLA binding motif for A2, with the preferred leucine at
position 2 and valine at position 9 (19).
The CTL lines specific for N
 
236–50
 
 and N
 
173–181
 
 displayed
more uniform peptide dose–response curves, suggesting
Figure 1. Bulk culture recognition of PUUV proteins. PBMCs (4–5  
106) were stimulated with 20  l of infectious PUUV (strain K27; 2.6  
106 pfu/ml) and cytotoxicity assays were performed using autologous
BLCLs infected with recombinant vaccinia viruses expressing PUUV N,
G1, G2/Bs or G2/Sm protein as targets. The recombinant vaccinia virus
designated vac-G2/Bs contains the first half of the G2 cDNA (amino acids
1 to 256), and the recombinant designated vac-G2/Sm contains the sec-
ond half of the G2 protein (amino acids 227 to 490). E/T ratios were ei-
ther 60:1 or 80:1. Unlabeled wild-type vaccinia virus infected BLCL were
included in all wells at a ratio of 10:1 unlabeled: labeled targets, to reduce
levels of vaccinia virus-specific lysis. Data shown represent the percent
specific lysis after subtraction of wild-type vaccinia virus background lysis.
Responses  10% above background were considered positive. 
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that their TCRs have similar affinities for the peptide–
MHC complex (Fig. 2, B and C). It is interesting to note
that we identified both B7-restricted (3-C8 and 10-F5)
and B8-restricted (10-G4) CTL lines that recognized the
same epitope (Table I). This peptide (RPKHLYVSM)
conforms to the defined HLA B7 motif reasonably well,
with the preferred proline at position 2 and a methionine
at position 9 (L or F preferred); and to the B8 motif less
well, with the preferred lysine at position 3 and a leucine
at position 5 (K or R preferred; reference 19). The second
B8-restricted CTL epitope (N243–51: ECPFIKPEV) con-
forms to the B8 motif very poorly. This highlights the fact
that natural CD8
 
 
 
 T cell epitopes do not necessarily con-
form to published HLA-binding motifs. Overall, these data
show that individuals who had past PUUV infections de-
veloped broad CTL cell responses to at least four epitopes
on the N protein.
 
CTL Lines Isolated from Donors 1 and 2 Are Primarily
PUUV-specific.
 
Next, we tested whether the CTL lines
isolated from donors 1 and 2 were cross-reactive with other
human hantaviruses. To do this, we tested whether these
CTL lines could recognize autologous BLCLs infected
with recombinant vaccinia viruses expressing either
PUUV, HTNV, or SNV N proteins (Table I). The CTL
lines specific for N
 
202–12
 
 failed to recognize the N protein
from either HTNV or SNV virus. The sequences of
HTNV and SNV N proteins both differ from the PUUV
sequence at this epitope by four amino acids, including a V
to A change at the anchor position 9 (Table II). Of the two
B7-restricted and one B8-restricted CTL lines that recog-
nize PUUV N
 
173–81
 
, only clone 10-F5 displayed cross-reac-
tive recognition of the HTNV N protein. This epitope is
well conserved among the viruses, with the HTNV and
SNV epitopes containing two conservative amino acid
 
Table I.
 
PUUV N-specific CD8
 
 
 
 CTL Lines
 
Donor CTL line Epitope HLA restrict. PUUV
% Specific lysis
 
a
 
 
HTNV V SNV N
1 1A-C11 N204-12 A2 44.7
 
 
 
1.1
 
 
 
1.1
1A-D10 N204-12 A2 41.5
 
 
 
1.2
 
 
 
3.3
1A-E5 N204-12 A2 49.6
 
 
 
5.6
 
 
 
3.8
1B-C3 N204-12 A2 50.6
 
 
 
1.7
 
 
 
1.4
3-C3 N204-12 A2 36.4
 
 
 
2.8
 
 
 
3.9
3-D10 N204-12 A2 56.3
 
 
 
4.6
 
 
 
6.6
3-E4 N204-12 A2 41.4
 
 
 
6.9
 
 
 
8.2
3-E11 N204-12 A2 43.4
 
 
 
3.0
 
 
 
6.7
10-B10 N204-12 A2 37.6
 
 
 
2.8
 
 
 
3.9
1 3-C8 N173-81  B7 18.0
 
 
 
7.8
 
 3.7
10-F5 N173-81  B7 33.6 25.5 0.5
10-G4 N173-81  B8 22.4 2.7  1.8
1 1A-G6 N243-51 B8 76.7 ND ND
2 1A-D11 N236-50 ND 19.1  1.0 2.2
1B-G9 N236-50 ND 20.3  1.8 22.0
3-B2 N236-50 ND 19.3  0.3 3.2
3-E9 N236-50 ND 24.0 3.1 2.2
10-B4 N236-50 ND 18.2 2.0 2.7
10-B5 N236-50 ND 17.9 0.9 3.8
10-E11 N236-50 ND 20.8 2.6 1.7
2 3-D3 N212-20 ND 27.3  1.7  3.5
3-D3 N212-20 ND 27.6 0.4 1.9
2 3-B8 N164-78 A28 27.4 25.9  3.0
aE/T   10.583 Van Epps et al.
changes, and with both expressing the preferred P at posi-
tion 2 (Table II).
The CD8  CTL lines that recognize PUUV N236–250 are
also primarily PUUV-specific with most displaying no rec-
ognition of targets expressing either the HTNV or SNV N
protein. However, one CTL line (1B-G9) consistently rec-
ognized targets expressing the SNV N protein as well as
those expressing the PUUV N protein (Table I). The se-
quence at this epitope is extremely variable among different
hantaviruses (Table II), and it is surprising that this CTL
line was able to recognize the corresponding sequence
from the SNV N protein.
Neither of the cell lines that recognize PUUV N212–20
was cross-reactive with HTNV or SNV N protein, despite
a relatively high level of sequence conservation at this
epitope (Table II). The N212–20 peptides from the PUUV,
HTNV, and SNV N proteins share the same amino acids at
the putative anchor positions 2 and 9 (R and M, respec-
tively). However, since we have not yet determined the
HLA restriction of these CTL lines, we cannot accurately
predict which residues within the epitope might be critical
for recognition of the peptide-HLA complex by the TCR
or for binding of this peptide to the HLA molecule. Fi-
nally, the CTL line that recognizes N164–178 (3-B8) is cross-
reactive with the HTNV N protein, but does not recog-
nize the SNV N protein. This epitope is relatively well
conserved between PUUV and HTNV, with the corre-
sponding epitope on HTNV N differing by three amino
acids and less well conserved between PUUV and SNV,
which differ by six amino acids at this epitope.
In summary, of 22 CTL lines tested against HTNV and
SNV viruses only three CTL lines showed cross-reactive
lysis, suggesting that the CTL responses identified in this
study were highly PUUV-specific. None of these cross-
reactive CTL lines recognized the N protein from both
HTNV and SNV viruses, despite the fact that some of the
epitopes share considerable sequence identity among the
different hantaviruses.
PUUV-specific Memory CD8  T Cells Circulate at High
Frequencies in Immune Individuals. To determine whether
the epitopes identified in this study are commonly targeted
in infected individuals, we studied a panel of PBMCs from
13 PUUV-immune donors, including the seven donors in
which PUUV-specific responses were detected in bulk cul-
tures (Fig. 1). Using IFN-  ELISPOT assays, we deter-
mined the frequency of epitope-specific CD8  T cells in
the memory pool.
Of the 13 individuals tested, eight had detectable
PUUV-specific T cell responses to one or more PUUV N
epitope (Fig. 3). Three individuals had high frequencies of
circulating PUUV N-specific memory T cells (donors 1,
11, and 13; Fig. 3 A), with some epitope-specific T cells
present at frequencies as high as 300 per 106 PBMCs. The
hierarchy of epitope recognition varied from donor to do-
nor, with different epitope-specific populations dominating
in different individuals.
Five additional donors (donors 2, 6, 7, 9, and 10) had
somewhat lower frequencies of memory cells specific for
these epitopes (Fig. 3 B), again with a variable hierarchy of
recognition. The frequency of individual epitope-specific
T cells seen in these donors was between 13 and 61/106
PBMCs. These responses are comparable to frequencies of
many commonly recognized influenza virus epitopes (18,
20). In fact, when the three A2  donors in this study were
stimulated with the influenza A virus peptide M158–66 in
ELISPOT assays, none of the donors had detectable re-
sponses to this epitope.
A summary of the range of precursor frequencies seen in
these donors is shown in Table III. Of the three epitopes
for which T cell responses were detected, the A2-restricted
epitope (N204–12) and the B8-restricted epitope (N243–51)
were recognized most consistently, with detectable re-
Figure 2. CTL activity of PUUV N-specific CD8  T cell clones iso-
lated from donor 1 against autologous BLCL target cells pulsed with in-
creasing dilutions of the optimal peptide. E/T   10. (A) CTL lines spe-
cific for the A2-restricted epitope N204–12. (B) CTL lines specific for the
B7,B8-restricted epitope N173–81. (C) CTL line specific for the epitope
N236–50. Lysis of targets not pulsed with peptide was  5% in all assays.584 Human T Lymphocyte Responses to Puumala Virus Infection
sponses to the former seen in all A2  donor tested (3/3)
and to the latter in 8 of 12 B8  donors tested. The N173–81
(B7 or B8 restricted) was recognized in only 2 of 12 do-
nors (Table III). We did not detect IFN-  responses to the
N164–78 epitope in any of the A28  donors tested, includ-
ing the donor from which the N164–78-specific clone was
isolated (donor 2). Since we used a 15-mer peptide to
stimulate the PBMCs in the ELISPOT assays, the condi-
tions for stimulation may have been suboptimal. It is also
possible that the frequencies of T cells specific for this
epitope were below the limit of detection. These data
demonstrate that PUUV N-specific memory CTL are
abundant in the peripheral blood of immune individuals
for many years after acute infection, and that detection of
these memory CTL populations does not require pro-
longed in vitro restimulation.
We did not detect responses to any of the four CD8 
epitopes tested in the PBMCs of the other five donors (do-
nors 3, 4, 5, 8, and 12). It is clear that virus-specific mem-
ory T cells are present in the PBMCs of these donors, since
N-specific CTL activity is detectable in at least three of
these donors PBMCs (donors 3–5) after 7 d of in vitro
Table II. Sequence Comparison of Epitopes between PUUV, HTNV, and SNV Viruses
N204-12 PUUV G L F P T Q I Q V
HTNV G L Y P A QIKA
SNV G L F P A Q VKA
N173-81 PUUV R P K H L Y V S M
HTNV K PKHLYVSL
SNV K P R HLYVSM
N243-51 PUUV E C P F I K P E V
HTNV P C KLLPD TA
SNV R CP F LPEQK
N236-50 PUUV I R E F M E K E C P F I K P E
HTNV I EQWL I EPC KLLPDT
SNV I DD F LAARCPFLPEQ
N212-20 PUUV V R N I M S P V M
HTNV A R QM I SPV M
SNV A RN I I SPV M
N164-78 PUUV T S F E D I N G I R R P K H L
HTNV S SFEDV NG I RK PKHL
SNV S S Y E EVNG I RK P R HL
Figure 3. Detection of virus-specific CD8  memory T cells by IFN-  ELISPOT. PBMCs were stimulated with 10  g/ml of the indicated peptides in
a 16–18 h assay. Input cell numbers ranged from 2–4   106 cells per well. Peptide stimulations were performed in triplicate wells. PBMCs stimulated
with a B8-restricted epitope from HCV NS3 (NS31402–1411) was included for comparison with PUUV-specific B8-restricted epitopes. PBMCs incubated
with media alone was included as negative controls. The data is presented as the number of IFN-  producing cells/106 PBMCs, with media control val-
ues subtracted. The number of spots in the media control wells ranged from 0 to 5. All ELISPOT experiments were performed at least twice and mean
values are shown. (A) PUUV-immune individuals who had high precursor frequencies ( 100 specific T cells/106 PBMC) of CD8  T cells specific for
one or more CD8  epitopes on PUUV N. (B) PUUV-immune individuals who had lower precursor frequencies of CD8  T cells specific for one or
more CD8  epitopes on PUUV N.585 Van Epps et al.
stimulation with infectious PUUV (Fig. 1). Undoubtedly,
there are other CD8  epitopes on the N protein that have
not yet been identified, and that CTL with distinct speci-
ficities contribute to the CTL response seen in these do-
nors. We have also demonstrated proliferation in response
to inactivated PUUV in PBMCs from these donors (un-
published data), further demonstrating that these donors
possess virus-specific memory T cells.
To determine whether the maintenance of PUUV-spe-
cific memory T cells was due to the persistence of virus, we
performed nested RT-PCR on PBMCs and urine samples
from PUUV immune donors, including 9 donors enrolled
in the present study and seven donors from previous studies
(21, 22). We were unable to detect viral RNA in convales-
cent PBMC or urine samples from any individual (unpub-
lished data). In vitro, this assay is capable of detecting as few
as 10–100 copies of viral RNA (unpublished data).
Discussion
In this study, we analyzed the memory CD8  T cell re-
sponses in PUUV immune individuals. The majority of
PBMCs from immune individuals stimulated with live
PUUV recognized the viral nucleocapsid, and the N pro-
tein was the target of the majority of CTL lines isolated
from two immune individuals. In contrast, the PUUV G1
glycoprotein was recognized at the bulk culture level in 5
of 7 donors, but we were able to isolate only a single G1-
specific CTL line (17). These data, as well as the high pre-
cursor frequency of N-specific CD8  T cells observed in
many of the immune donors, suggest that the N protein
may be the dominant target of CD8  CTL during PUUV
infection. Six CD8  CTL epitopes on N protein were
identified in this study (Table I). The hierarchy of the
epitope-specific CD8  T cell populations differed between
individuals, suggesting that no single epitope was immuno-
dominant. The CTL response in two donors was simulta-
neously targeted to at least four epitopes on PUUV N and
was restricted by a variety of HLA alleles, thus demonstrat-
ing a diverse PUUV-specific T cell repertoire. The identi-
fication of PUUV-specific CD8  T cell epitopes provides
framework for future studies of PUUV-specific CTL re-
sponses during acute HFRS, allowing us to evaluate the ki-
netics and magnitude of the virus-specific T cell response
and the potential role of T cell activation in the pathology
of disease.
There are at least 20 distinct hantaviruses, approximately
half of which are known to cause human disease. We were
interested in examining whether protective immunity
against one hantavirus confers immunity against other
strains of hantavirus. This is an important consideration in
geographic regions where more than one hantavirus cocir-
culates (23, 24). In a previous study, CTL responses di-
rected against a conserved epitope on HTNV N protein
were found to be highly cross-reactive, while CTL specific
for another, more variable, epitope were HTNV-specific
(16). The epitopes identified in this study are clustered near
the center of the PUUV N protein in a region that shares
relatively little sequence identity among the different han-
taviruses. It was not surprising, therefore, to find that the
majority of the CTL lines isolated in this study failed to
recognize target cells expressing the N protein from either
HTNV or SNV. In previous studies, B cell epitopes in hu-
mans and protective epitopes in bank voles were all
mapped to the amino-terminal third of the N protein (25,
26). This suggests that distinct regions of the N protein are
targeted by B and T cells during the immune response to
PUUV. This may be an important consideration in the de-
sign of effective vaccines capable of eliciting both neutraliz-
ing antibodies and antiviral CTL.
Perhaps the most provocative finding of this study is that
PUUV-specific memory CTL were maintained at high fre-
quencies in individuals who had clinical infections with
PUUV 6–15 y earlier, without evidence of continued anti-
genic stimulation. There is no evidence of persistent han-
tavirus infection, and clinical reinfections with PUUV or
other human hantaviruses have never been reported. Viral
RNA can be easily detected during within the first 9 d of
symptomatic PUUV infection, but convalescent samples
( 10 d after the onset of symptoms) are consistently PCR
negative (21, 22, 27, 28). Similarly, patients with acute
HPS have been shown to have high plasma levels of SNV
RNA as detected by competitive RT-PCR, but viral
RNA is rapidly cleared and becomes undetectable during
Table III. Recognition of CD8+ PUUV Epitopes in PBMCs from Immune Donors by IFN-  ELISPOT
Epitope HLA-restriction
Number of 
donors testeda
Number of 
responders
Range of IFN- –producing
T cells/106 PBMCs
N 173-181 B7, B8 12 2 52-304
N 243-251 B8 12 8 13-188
N 204-212 A2 3 3 16-200
N 164-178 A28 3 0 NDb
Flu M158-66 A2 3 0 ND
aTested only donors possessing the indicated HLA allele.
bBelow the limit of detection.586 Human T Lymphocyte Responses to Puumala Virus Infection
convalescence (29, 30). To further address the question of
virus persistence, we performed nested RT-PCR analysis
on PBMCs and urine samples taken from 17 PUUV-
immune individuals, including nine donors from this study.
For ten of these donors, PCR analysis was performed dur-
ing the acute phase of illness, and five had detectable
PUUV RNA in their PBMCs or urine at that time. In
agreement with published results, PUUV RNA was unde-
tectable in all convalescent PBMCs and urine samples
tested, suggesting that high levels of memory T cells persist
in the absence of detectable virus.
There has been considerable debate regarding the role of
antigen in the maintenance of memory CD8  T cells. The
definitive studies were performed in murine models in
which LCMV-specific CD8  T cells were transferred into
naive wild-type or class I–deficient mice. These studies
clearly demonstrated that the survival of memory CD8  T
cells requires neither persistent antigen nor the expression
of MHC class I molecules on host cells (31, 32). Similar
studies performed in B cell–deficient mice also ruled out
the possibility that the survival of memory T cells relies on
depots of antigen trapped on follicular dendritic cells in the
form of antigen–antibody complexes (33). In humans, vac-
cinia virus-specific memory CTL responses have been de-
tected in individuals who were vaccinated up to three de-
cades ago. Since vaccinia virus does not cause a chronic
infection in humans and reexposure to the virus is unlikely,
the maintenance of T cell memory in this system also ap-
pears to be antigen independent (34).
The frequencies of PUUV-specific memory CTL re-
ported here are comparable or higher than frequencies of
CTL specific for many commonly recognized epitopes on
influenza A virus. (18). In one study, the highest precursor
frequencies of memory CD8  T cells specific for dominant
influenza A virus epitopes on the M1 and NP proteins
ranged from 9–286/106 PBMCs and 15–67/106 PBMCs,
respectively (18, 20). The highest frequencies of PUUV
N-specific T cells measured in this study were 52–304/106
and 16–200/106 PBMCs. Interestingly, none of the three
A2  donors in this study had detectable responses to the in-
fluenza A virus M1 epitope (Table III). Like PUUV, influ-
enza virus causes an acute infection that is rapidly cleared
by the immune system. However, influenza virus is able to
periodically reinfect individuals with existing influenza vi-
rus-specific T cell memory, and thus boost T cell responses.
While periodic exposures to PUUV may occur, secondary
infections have never been reported for this or any other
human hantavirus. High levels of PUUV-specific neutraliz-
ing antibodies circulate after resolution of infection and
these antibodies can be detected for many years (35–37).
These neutralizing antibodies probably prevent or mini-
mize the ability of the virus to establish a productive infec-
tion in host cells. As a result, the memory T cell response is
unlikely to be effectively boosted since viral antigens are
unlikely to gain access to the MHC class I processing path-
way and be presented by a significant number of host cells.
Indeed, the passive transfer of hantavirus-specific neutraliz-
ing antibodies in hamsters has been shown to provide pro-
tection against subsequent virus challenge, suggesting that
the presence of neutralizing antibodies prevented the virus
from establishing a productive infection (38).
Frequency analysis of measles virus-specific CTL in
healthy adult donors who had childhood infections with
measles reported that 100–960 cells per 106 PBMCs were
virus-specific (39). In this study measles-infected BLCLs,
rather than defined peptide epitopes, were used as stimula-
tor cells in IFN-  ELISPOT assays. Therefore, these num-
bers reflect the total of all measles virus-specific T cells ca-
pable of producing IFN-  in these donors. The total
frequency of the PUUV-specific T cells analyzed in the
present study was between 13 and 444/106 PBMCs. Since
we measured the responses to only four CD8  CTL
epitopes, restricted by only four possible HLA alleles (A2,
A28, B7, B8), we are probably underestimating the total
PUUV-specific T cells response in these donors. The fre-
quencies of virus-specific memory CD8  T cells measured
in the present study are also comparable to the frequencies
of some virus-specific CTL in adult donors with chronic
virus infections such as EBV and HIV (40–43). In these
systems, CTL precursor frequencies are often very high,
probably due to periodic reactivation as a result of the per-
sisting virus infection.
Overall, the data show that the frequencies of epitope-
specific CD8  T cells in PUUV-immune individuals are
remarkably high and are comparable to or exceed those
measured in other acute virus infections such as influenza
and measles. The reported frequencies are also comparable
to those measured in chronic virus infections such as EBV
and HIV. This is notable given the fact that the primary
PUUV infections in these individuals occurred between 6
and 15 y earlier, and that PUUV RNA is no longer detect-
able as early as 9 d after the onset of acute illness. This sys-
tem provides a rare opportunity to study the development
and maintenance of antiviral CD8  T cell memory in hu-
mans after an acute infection in the absence of detectable
persisting virus.
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